Rabies Monoclonal Antibody Market By Product Type (Single Monoclonal Antibody, Combination Monoclonal Antibodies, Bispecific Monoclonal Antibodies); By Administration Mode (Wound-Site Infiltration, Intramuscular Administration, Combination Administration); By End User (Public Hospitals, Private Hospitals, Anti-Rabies Clinics, Government Immunization Programs, NGO & Donor-Funded Programs); By Distribution Channel (Hospital Pharmacies, Government & NGO Supply Chains, Retail Pharmacies, Online Pharmacies); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Rabies Monoclonal Antibody Market: Recombinant Supply Expands Where Passive Immunization Remains Limited

The Global Rabies Monoclonal Antibody Market is projected to grow from USD 210.61 million in 2025 to USD 0.45 billion by 2032, expanding at a robust CAGR of 11.6%, according to internal estimates by Strategic Market Research.

 

The Rabies Monoclonal Antibody Market is developing around a persistent weakness in global post-exposure care: rabies vaccines are more widely available than the passive antibodies required after severe exposure. Rabies causes an estimated 59,000 deaths annually, with more than 95% occurring in Asia and Africa. Children below 15 years account for approximately 40% of deaths, while infected dogs cause up to 99% of human cases. Once clinical symptoms appear, rabies is almost always fatal, but timely post-exposure prophylaxis can prevent death.

 

WHO recommends wound cleaning, vaccination and passive immunization for Category III exposures, including bites or scratches that break the skin, saliva entering damaged skin or mucous membranes, and direct bat exposure. Rabies monoclonal antibodies, or RmAbs, are laboratory-produced proteins that neutralize the virus before it reaches peripheral nerves. They provide immediate protection while the vaccine generates an active immune response.

 

RmAbs do not replace rabies vaccines. They replace or supplement the passive-immunization role traditionally served by human rabies immunoglobulin, or HRIG, and equine rabies immunoglobulin, or ERIG. Their commercial value lies in standardized recombinant production, consistent potency and reduced dependence on donated plasma or animal-derived serum.

 

Global PEP Volumes Create a Large but Uneven Market

Published estimates of annual rabies treatment volumes vary because some sources count complete PEP courses while others count vaccine recipients. Older estimates commonly cited more than 15 million people receiving post-bite vaccination each year, while Institut Pasteur estimates approximately 17 million annual PEP recipients. WHO currently reports more than 29 million people receiving human rabies vaccines annually. These measures are not directly interchangeable, but they confirm that rabies prevention operates at a scale far larger than annual mortality figures suggest.

Only part of this population requires a monoclonal antibody or immunoglobulin. Category II exposures generally require wound care and vaccination, while Category III exposures create passive-immunization demand. Previously vaccinated patients usually do not require RIG or RmAbs.

The strongest market opportunity is concentrated in countries with high dog-bite volumes, low prior vaccination rates and weak passive-antibody availability. India, China, Southeast Asia and Africa carry the largest access gap. The United States and Europe have lower patient volumes but higher treatment values, established hospital purchasing systems and stricter regulatory requirements.

 

Passive Immunization Remains the Main Treatment Bottleneck

HRIG and ERIG have prevented rabies deaths for decades, but both products face supply constraints. HRIG depends on plasma from immunized donors and is comparatively expensive. ERIG is generally cheaper but relies on animal-based production and may face procurement, acceptance and safety concerns.

WHO found that passive immunization remained negligible in several high-burden settings. In one Indian study, only 21 of 783 at-risk patients were prescribed HRIG and only ten could afford it. Other studies in India and Thailand found that only 2% to 3% of severely exposed patients received RIG. These gaps show that vaccine availability alone does not ensure complete protection after severe exposure.

RmAbs address this problem through planned recombinant manufacturing. Production can be expanded through bioreactor capacity, standardized quality testing and repeatable cell-culture processes. Manufacturers can also offer different concentrations and vial sizes to reduce unused product across patients of different weights.

WHO added anti-rabies monoclonal antibodies to its core Model Lists of Essential Medicines for adults and children in 2021. The listing recognized their potential to expand procurement options and reduce dependence on constrained HRIG and ERIG supply. It also created a future route for quality-assured biosimilar competition.

 

India Combines the Largest Access Gap with First-Mover Manufacturing

India is the most established commercial market for rabies monoclonal antibodies. Longstanding estimates place annual animal bites at approximately 17.4 million to 20 million and attribute around 18,000 to 20,000 deaths to rabies each year. WHO burden modelling has estimated that India contributes roughly 35% of global rabies deaths.

More recent community research estimated about 9.1 million animal bites annually, with dogs accounting for 76.8%. The lower figure reflects differences in survey design and reporting methods rather than a precise measure of decline. Both estimates indicate sustained pressure on vaccines, RIG and anti-rabies clinics.

India’s market depends heavily on public hospitals, municipal clinics and government procurement. A nationwide survey covering 534 facilities across 60 districts and 15 states found anti-rabies vaccines in 79.7% of public facilities but RIG in only 20.3%. Rural and lower-level facilities showed the largest gaps.

This difference has direct commercial consequences. Patients may begin vaccination locally but travel to district hospitals or medical colleges for passive immunization. Distance, lost wages and treatment delays reduce completion, particularly in rural areas. Manufacturers with district-level distribution and state tender access can reach a much larger market than suppliers focused only on private hospitals.

 

Rabishield Established the First Commercial RmAb Category

Serum Institute of India developed Rabishield with MassBiologics at UMass Medical School. Approved in India in 2016 and launched in 2017, it became the first commercially available human monoclonal antibody for rabies passive immunization.

Rabishield is administered at 3.33 IU per kilogram of body weight. The product is infiltrated into and around the wound, with any remaining volume injected intramuscularly at a site distant from the vaccine. It is supplied in 100 IU and 250 IU presentations.

Its low weight-based dose can reduce treatment volume compared with conventional immunoglobulin, although actual savings depend on body weight, wound number, vial size and tender price. Serum Institute also benefits from an established vaccine distribution network, allowing the company to position Rabishield within a broader PEP portfolio.

Post-marketing evidence has strengthened its procurement position. Large Indian studies have reported strong immune responses, mostly mild adverse reactions and no rabies cases during follow-up among treated patients. Real-world evidence is especially important for government buyers because it includes children, multiple wounds and routine hospital populations.

 

TwinRab Expanded Competition into Antibody Cocktails

Zydus received Indian authorization for TwinRab in 2019. The product combines docaravimab and miromavimab, which bind to different regions of the rabies virus. The cocktail format is intended to broaden neutralization coverage and reduce the risk of viral escape from a single antibody.

TwinRab gave Indian hospitals a second recombinant option and widened comparison across single-antibody RmAbs, antibody cocktails, HRIG and ERIG. Procurement decisions now consider cost per treated patient, local clinical experience, pack sizes, distributor reach and supply reliability.

A 2025 observational study involving 159 patients with severe animal bites reported adverse events in 10.7% of participants, mainly mild local reactions. No severe systemic reactions or rabies cases were recorded during six months of follow-up.

 

China Is Broadening the Product Landscape

By 2025, four RmAb products had received authorization across India and China: Rabishield and TwinRab in India, Ormutivimab in China in 2022, and the zamerovimab–mazorelvimab combination in China in 2024. China’s entry created a second major manufacturing centre and reduced the market’s dependence on Indian suppliers.

Ormutivimab became China’s first commercial recombinant human anti-rabies monoclonal antibody. Zamerovimab–mazorelvimab, also known during development as SYN023, added a two-antibody format and was studied in more than 1,100 recipients, including nearly 1,000 Category III exposure cases.

China expanded the category again in June 2026 with approval of Silevimig, described by its developer as the first fully human bispecific antibody approved for passive rabies immunization. The product targets two viral sites within one antibody structure. Its adult Phase III trial met the primary non-inferiority endpoint against HRIG, while paediatric development continued.

Competition is now shifting from a simple RmAb-versus-RIG comparison toward competition among single-antibody, cocktail and bispecific formats. Chinese suppliers could also become important exporters across Asia, Africa and Central Asia.

 

Clinical Evidence Is Moving Beyond Registration Trials

Rabies prevention creates an unusual trial challenge because investigators cannot ethically withhold effective PEP and wait for rabies deaths. Regulators and WHO therefore accept rabies-virus-neutralizing antibody levels as a primary clinical measure, supported by follow-up and post-marketing surveillance.

Trials reviewed by WHO found that RmAb regimens produced immune responses comparable with conventional RIG-based PEP. No rabies deaths were reported in the assessed clinical programmes, although continued surveillance remains important for children, pregnant women and older patients.

Large Phase IV and observational studies in India are making RmAbs more credible to tender committees. Public buyers are more likely to replace an established immunoglobulin when evidence comes from routine treatment populations rather than only healthy volunteers or small registration trials.

 

The United States Remains a High-Value HRIG Market

The United States has largely eliminated dog-mediated human rabies, but wildlife exposure continues to generate substantial PEP demand. Bats, raccoons, skunks and foxes account for most reported animal rabies cases, while bat contact drives much of the domestically acquired human risk.

Approximately 60,000 annual PEP courses remain the widely cited historical benchmark. More recent CDC reporting places the number closer to 100,000 people receiving PEP each year following about 1.4 million healthcare evaluations for possible exposure. Human rabies remains rare, historically averaging one to three deaths annually.

Current U.S. treatment remains HRIG-led. CDC recommends wound care, HRIG and a vaccine series for previously unvaccinated patients. No RmAb has yet replaced HRIG in routine national guidance.

The FDA has issued guidance for monoclonal antibody cocktails as alternatives to RIG. U.S. development must show neutralization against North American bat, raccoon, fox and skunk-associated variants rather than relying only on evidence from dog-mediated strains in Asia. A successful product would compete on standardized production, treatment volume and total PEP cost, but adoption would still require support from CDC, state health departments and hospital specialists.

 

Europe Is a Specialist Travel and Preparedness Market

Dog-mediated rabies has been nearly eliminated across most of Western and Central Europe. Demand is concentrated among travellers returning from endemic countries, imported animal exposures, specialist emergency departments and exposure to European bat lyssaviruses.

Between 1977 and 2025, researchers identified 285 human rabies cases across Europe, most in Russia, Ukraine and Georgia. Within the EU and EEA, cases have been rare and frequently associated with travel. Europe therefore represents a lower-volume but potentially higher-value market for travel medicine, emergency preparedness and national stockpiles.

Market entry will depend on European regulatory approval, pharmacovigilance, dependable supply and evidence covering bat-associated lyssaviruses as well as classical rabies virus.

 

Gavi Vaccine Expansion Could Reveal a Larger Antibody Gap

Gavi began supporting human rabies vaccines for PEP in eligible countries in 2024, with more than 50 countries potentially able to apply for assistance. The programme is intended to expand vaccine access in underserved communities across Africa and Asia.

The programme does not currently finance RmAbs or RIG. Wider vaccine availability may therefore expose a second bottleneck as more Category III patients enter formal PEP systems but remain unable to obtain passive immunization. This creates a potential route for national tenders, donor partnerships and pooled purchasing.

Africa carries a substantial share of global rabies deaths but has limited passive-immunization access outside major cities. Converting that need into a commercial market will require public financing, registrations across multiple countries, affordable pack sizes and district-level distribution.

 

Procurement Economics Will Decide Market Leadership

The market is moving from a two-product Indian category toward a broader Asian biologics segment. Serum Institute and Zydus retain first-mover advantages, while Ormutivimab, zamerovimab–mazorelvimab and Silevimig are widening competition in China.

Public buyers will compare total cost per treated patient rather than vial price alone. Dose, concentration, vial wastage, wound-infiltration volume, shelf life, cold-chain requirements, paediatric evidence and supply continuity all influence procurement.

ERIG will remain relevant in highly price-sensitive programmes, while HRIG will remain established in the United States and other high-income markets. RmAbs occupy the space between them: more scalable and standardized than plasma-derived HRIG, but still dependent on competitive pricing and reliable distribution.

Long-term demand will decline only when dog-mediated rabies is brought under control. Until vaccines, passive antibodies and bite-management services are available at the same point of care, the difference between Category III exposure volumes and RIG access will continue to support the Rabies Monoclonal Antibody Market

 

Rabies Monoclonal Antibody Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026–2032
Market Size Value in 2025	USD 210.61 Million
Revenue Forecast in 2032	USD 450 Million
Overall Growth Rate	CAGR of 11.6% (2026–2032)
Base Year for Estimation	2025
Historical Data	2019–2024
Unit	USD Million, CAGR (2026–2032)
Segmentation	By Product Type, By Administration Mode, By End User, By Distribution Channel, By Geography
By Product Type	Single Monoclonal Antibody, Combination Monoclonal Antibodies, Bispecific Monoclonal Antibodies
By Administration Mode	Wound-Site Infiltration, Intramuscular Administration, Combination Administration
By End User	Public Hospitals, Private Hospitals, Anti-Rabies Clinics, Government Immunization Programs, NGO and Donor-Funded Programs
By Distribution Channel	Hospital Pharmacies, Government and NGO Supply Chains, Retail Pharmacies, Online Pharmacies
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, India, Japan, South Korea, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Persistent shortage of passive-immunization products for Category III rabies exposureGrowing adoption of standardized recombinant alternatives to human and equine rabies immunoglobulinsExpansion of public procurement, post-exposure prophylaxis programs and anti-rabies treatment infrastructure across Asia and Africa
Customization Option	Available upon request